Evidence map›Paper›PMID 40963416›Full record

ArticleChemMedChem2025

Development of a Partial Proteolysis Targeting Chimera Library Based on Achiral Cereblon E3 Ligase Ligands and its Application for Bruton's Tyrosine Kinase Degraders.

Chelsi M Almodóvar-Rivera, Ira Tandon, Ramesh Mudududdla, Paulina N Esguerra, Kevin Lucio-Acero, Weiping Tang

Abstract read
In one paragraph

Article in ChemMedChem, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Chelsi M Almodóvar-RiveraLachman Institute for Pharmaceutical Development, School of Pharmacy, University of Wisconsin-Madison, 777 Highland Avenue, Madison, WI, 53705, USA.
Ira TandonLachman Institute for Pharmaceutical Development, School of Pharmacy, University of Wisconsin-Madison, 777 Highland Avenue, Madison, WI, 53705, USA.
Ramesh MudududdlaLachman Institute for Pharmaceutical Development, School of Pharmacy, University of Wisconsin-Madison, 777 Highland Avenue, Madison, WI, 53705, USA.
Paulina N EsguerraLachman Institute for Pharmaceutical Development, School of Pharmacy, University of Wisconsin-Madison, 777 Highland Avenue, Madison, WI, 53705, USA.
Kevin Lucio-AceroLachman Institute for Pharmaceutical Development, School of Pharmacy, University of Wisconsin-Madison, 777 Highland Avenue, Madison, WI, 53705, USA.
Weiping TangLachman Institute for Pharmaceutical Development, School of Pharmacy, University of Wisconsin-Madison, 777 Highland Avenue, Madison, WI, 53705, USA.ORCID https://orcid.org/0000-0002-0039-3196

Funding

UW COMPREHENSIVE CANCER CENTER SUPPORTP30CA014520 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI Christian Capitini · 1985 to 2026
$142.6M
Graduate Training in Molecular and Cellular PharmacologyT32GM141013 · NIGMS · UNIVERSITY OF WISCONSIN-MADISON · PI Anjon Audhya, Aaron Matthew LeBeau · 2021 to 2026
$3.2M
Chemical Synthesis and Biological Application of Carbohydrates and Glycoconjugates - Admin SupplementR35GM148266 · NIGMS · UNIVERSITY OF WISCONSIN-MADISON · PI Weiping Tang · 2023 to 2026
$1.8M
Chemistry-Biology Interface Training ProgramT32GM152341 · NIGMS · UNIVERSITY OF WISCONSIN-MADISON · PI Helen E. Blackwell · 2024 to 2026
$1.6M
Lachman Institute for Pharmaceutical Development and UW Carbone Cancer Center NIH P30 CA014520National Institute of General Medical Sciences of the National Institutes of Health T32GM152341NCI NIH HHS P30 CA014520NIGMS NIH HHS R35 GM148266NIGMS NIH HHS T32 GM141013NIGMS NIH HHS T32 GM152341NIH HHS R35GM148266Wisconsin Alumni Research Foundation (WARF) UW2020
6 · The paper itself

Abstract

Proteolysis targeting chimeras (PROTACs) offer a promising therapeutic approach by leveraging the ubiquitin-proteasome system (UPS) to degrade target proteins. These heterobifunctional molecules consist of a target protein ligand, an E3 ligase ligand, and a linker. Among the limited E3 ligase ligands available, cereblon (CRBN) ligands are the most widely used. However, the stability and racemization of current chiral CRBN ligands pose challenges for developing CRBN-recruiting PROTAC therapeutics. Herein, a partial PROTAC library is reported incorporating an aldehyde motif and various linkers into previously developed achiral phenyl dihydrouracil CRBN ligands, which offer improved stability and eliminate racemization issues. This library enables the rapid generation of fully functional PROTACs targeting Bruton's tyrosine kinase (BTK) by coupling the aldehyde motif with a hydrazide-containing BTK ligand. Initial HiBiT assay (Promega) screening identifies nine hits capable of significant BTK degradation, with compound B1 emerging as the most potent degrader. A stable amide bioisostere, AM-B1, is further developed, which induces significant antiproliferation and BTK degradation. Mechanistic studies confirm BTK degradation via the UPS. This study highlights the development of an achiral CRBN-based partial PROTAC library and demonstrates a two-stage strategy for rapid PROTAC development against BTK.

Indexed as

Adaptor Proteins, Signal TransducingAgammaglobulinaemia Tyrosine KinaseAntineoplastic AgentsProtein Kinase InhibitorsSmall Molecule LibrariesUbiquitin-Protein LigasesDose-Response Relationship, DrugHumansLigandsMolecular StructureProteolysisProteolysis Targeting ChimeraStructure-Activity RelationshipAdaptor Proteins, Signal TransducingAgammaglobulinaemia Tyrosine KinaseAntineoplastic AgentsBTK protein, humanCRBN protein, humanLigandsProtein Kinase InhibitorsProteolysis Targeting ChimeraSmall Molecule LibrariesUbiquitin-Protein Ligasesachiral ligandsBruton's tyrosine kinasecereblonproteolysis targeting chimeras

Identifiers

PMID40963416
PMCPMC12471865

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.